

Paranta Presents at BIO Investor Forum, San Francisco

Melbourne, Australia 9 November 2017:

Paranta Biosciences is pleased to have been selected to present at BIO Investor Forum held in San Francisco, USA over 17-18 October 2017. BIO Investor Forum is an international biotech investor conference focused on early and established private companies as well as emerging public companies developing major new medical treatments. The event was attended by over 300 representatives of leading investment firms.

Paranta's CEO, Ross Barrow, presented to this exclusive investor audience on Wednesday 18 October. He showcased the Company and highlighted its lead therapeutic asset, PB01. The clinical importance of PB01's unique anti-inflammatory, anti-fibrotic and metabolic properties were discussed in relation to Paranta's lead development program in cystic fibrosis lung disease and the Company's preclinical pipeline in diabetic kidney disease and oncology.

In addition to the presentation, Ross and the Company's Commercial Director, Dr Amanda Reese, participated in a large number of one-on-one meetings with investors and other biotech industry groups over the two days. These meetings provided an excellent opportunity to profile the Company's commercial strategy and establish relationships with potential investors and partners.

Paranta's involvement in the BIO Investor Forum is part of a broader strategy to engage with the international investor community and includes the recent appointment of New York investor relations firm, Affinity Growth Advisors, to assist with the process.

A copy of Paranta's presentation can be accessed on the Company's website.

About Paranta

Paranta Biosciences Limited is a clinical-stage biopharmaceutical company developing potentially transformative first-in-class biotherapeutics based on PB01, a unique form of recombinant human follistatin, targeting inflammatory, fibrotic and metabolic diseases with significant unmet need.

The Company's lead program involves the development of an inhaled form of PB01 for treating cystic fibrosis lung disease. This program has completed Phase I clinical development. The Company has two programs in preclinical development. These programs involve the development of injectable forms of PB01 for treating diabetic kidney disease and the sensitization of cancers to platinum chemotherapy.

Paranta Biosciences is an unlisted Australian public company based in Melbourne, Australia.